Clinical performance of blood biomarkers across settings and countries
Both the mass spectrometry-based and fully automated assays demonstrated suitable performance for clinical implementation. However, a two-cutoff approach may be required in specific settings and subpopulations, particularly for the fully automated assays. Findings on clinicians' attitudes, the impact of PrecivityAD2 on clinical care, and comparisons between blood and cerebrospinal fluid (CSF) biomarkers using amyloid PET as the reference standard will also be presented.
Authors
- Philip B. Verghese (ORCID: https://orcid.org/0000-0003-4793-564X)
- Rik Ossenkoppele (ORCID: https://orcid.org/0000-0003-1584-7477)
- Erik Stomrud (ORCID: https://orcid.org/0000-0002-0841-5580)
- Pontus Tideman (ORCID: https://orcid.org/0000-0002-9620-7115)
- Nicholas Ashton
- Joel B. Braunstein (ORCID: https://orcid.org/0000-0002-1155-0206)
- Federica Anastasi (ORCID: https://orcid.org/0000-0002-9304-5421)
- S. Palmqvist
- Kaj Blennow
- Noëlle Warmenhoven
- Oskar H. Hansson
- Henrik Zetterberg
- Silke Kern
- Shorena Janelidze
- Andrea Pilotto
- Marc Suárez‐Calvet
- Niklas Mattsson‐Carlgren
Institutions
- University of Arizona (US)
- Lund University (SE)
- C2N Diagnostics (United States) (US)
- Pasqual Maragall Foundation (ES)
- Barcelonaβeta Brain Research Center (ES)
- University of Brescia (IT)
- University of Gothenburg (SE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_097509
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00